… Antiphospholipid antibodies (Abs) are associated with thrombosis and are a risk factor for …
Fluvastatin inhibits upregulation of tissue factor expression by antiphospholipid antibodies …

… occurring in a young male without the aforementioned risk factors. Thirteen patients (11%) …
disease and Black race were risk factors for thrombotic events in antiphospholipid patients. …

… morbidity and mortality is the antiphospholipid syndrome (APS) [10]. APS is a systemic
autoimmune disorder defined by the persistent presence of antiphospholipid antibodies (aPL) in …

… These studies suggested the possibility of anticoagulation discontinuation in PAPS patients
with low-risk and venous thrombosis with a concomitant risk factor that turned persistently …

… Both traditional and nontraditional cardiovascular risk factors are very prevalent in our
population and contribute for this increased incidence of atherosclerotic events. Nevertheless, we …

Antiphospholipid antibodies (aPL) have been implicated in the pathogenesis of coronary
artery disease (CAD). We evaluated the presence of aPL in patients with chest pain/acute …

… Our findings demonstrate that, after adjustment for cardiovascular risk factors, the presence
of aCL is associated with thrombosis. Furthermore, higher titres of aCL increase the odds for …

… Our data demonstrate that persistent positivity for LA is an important risk factor for the
development of APS in patients who present with ITP. Further studies are required to definitively …

… Antiphospholipid antibodies (aPL) are best considered as risk factors. aPL are not diagnostic
tests and considering them as such can be misleading and may direct attention away from …

… and epidemiological risks of arterial thrombosis, venous thrombosis, and pregnancy
morbidities in a large cohort of persistent antiphospholipid antibodies (aPLs)-positive carriers. …